干预性维生素混合玻璃眼研究 (IVMGS):对现有玻璃眼患者进行前性,随机化,双臂,单中心试验的研究方案
Navid Golpour1, Flora Hui2, Maria Nilsson1
1Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.
Trials
|October 14, 2025
概括
这项临床试验调查了针对单碳代谢的维生素补充是否可以保护视网膜细胞并改善青光眼患者的视力. 早期的结果表明潜在的神经保护和功能改善,提供了一个新的治疗途径.
科学领域:
- 眼科医生 眼科 眼科
- 神经科学是一个神经科学.
- 代谢医学是一种代谢医学.
背景情况:
- 玻璃眼瘤通过视网膜质细胞退化导致不可逆转的失明,目前的治疗方法侧重于眼内压力,但缺乏神经保护.
- 临床前研究表明,一碳代谢功能障碍在动物模型中导致青光眼神经退行症.
- 这项研究解决了对神经保护策略的需要,在绿眼管理.
研究的目的:
- 评估12个月补充一碳代谢辅因子 (维生素B6,B9,B12和胆) 的有效性,以改善内视网膜功能,并为绿眼病患者提供神经保护.
- 为了比较接受维生素补充剂加标准护理的患者和仅接受标准护理的患者之间的结果.
主要方法:
- 一个2a期,开放标签,随机临床试验,涉及80名轻度至中度青光瘤患者.
- 参与者每天接受一次碳代谢补充剂或标准护理.
- 主要结局:通过全场电网膜学改变光学负反应;次要结局:视野参数,视网膜神经纤维层和质细胞内状层厚度.
主要成果:
- 本节不适用,因为该研究正在进行中,结果尚未提供.
结论:
- 单碳新陈代谢补充剂在动物玻璃眼模型中表现出神经保护作用.
- 这项试验旨在验证补充剂是否可以增强视网膜功能和神经保护在人类绿眼中.
- 成功的结果可以建立一个低成本的,可访问的神经保护疗法治疗青光眼,补充现有的治疗方法.
关键词:
B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12 B12B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B9 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B2 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B2 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B2 B1 B1 B1 B1 B1 B1 B2 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B2 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1 B1胆结节 (Coline) 是一个结节.电网光学图 (Electroretinography) 是一种电网光学图.眼光障碍症是什么 眼光障碍症是什么神经保护是一种神经保护.一个碳代谢的一个碳代谢.摄影的负面反应反应.协议 协议 协议 协议 协议随机对照试验是随机对照试验.维生素B6 维生素B6 是一种维生素.相关概念视频
Open Angle Glaucoma: Treatment
961
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
961
Angle Closure Glaucoma: Treatment
1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K
Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K


